Physician profile
Steven Nack
NPI 1427096304
$7,783.50
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $767 · 2021: $744 · 2022: $1,362 · 2023: $2,233 · 2024: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685 · Education: $26.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,684.69 |
| Education | $26.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,519.37 | 2019-2024 | |
| Janssen Biotech, INC. | $815.95 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $609.92 | 2019-2024 | Xifaxan |
| Pfizer INC. | $493.59 | 2019-2024 | |
| Braintree Laboratories, INC. | $483.53 | 2019-2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $387.34 | 2019-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $323.80 | 2019-2024 | |
| Celgene Corporation | $323.54 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $229.81 | 2019-2024 | Dificid |
| Celltrion USA INC. | $171.27 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $131.02 | 2019-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $115.77 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $111.63 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $109.75 | 2024 | Voquezna |
| Amgen INC. | $95.36 | 2020-2023 | Amjevita |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $90.11 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $82.98 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $71.49 | 2020-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $66.42 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $66.04 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $61.36 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $57.63 | 2019-2020 | |
| Lilly USA, LLC | $55.76 | 2024 | Omvoh |
| Allergan, INC. | $37.48 | 2019 | |
| Boston Scientific Corporation | $35.85 | 2024 | Compliance Endokit, Endoarmor |
| Shionogi INC | $35.24 | 2019 | |
| Biofire Diagnostics, LLC | $33.19 | 2019 | |
| Medtronic, INC. | $28.43 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.13 | 2023 | |
| Shire North American Group INC | $23.51 | 2019 | |
| Alfasigma USA, INC. | $19.55 | 2020 | |
| Pharmacosmos Therapeutics INC. | $19.48 | 2023 | Monoferric |
| Ardelyx, INC. | $18.79 | 2023 | Ibsrela |
| Olympus America INC. | $17.92 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $16.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.